Other
Desoximetasone topical spray, 0.25% is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.
Apply desoximetasone topical spray, 0.25% as a thin film to the affected skin areas twice daily. Rub in gently.
Do not bandage or otherwise cover or wrap the treated skin unless directed by the physician.
Discontinue treatment when control is achieved.
Treatment beyond 4 weeks is not recommended.
Do not use if atrophy is present at the treatment site.
Avoid use on the face, axilla or groin.
Desoximetasone topical spray, 0.25% is for external use only. It is not for oral, ophthalmic, or intravaginal use.
Topical Spray, 0.25%. Each gram of desoximetasone topical spray contains 2.5 mg of desoximetasone USP in a clear, colorless liquid.
None
Desoximetasone topical spray, 0.25% can be absorbed in sufficient amounts to produce systemic effects. [see Warnings and Precautions (5.1)]
Desoximetasone topical spray, 0.25% for dermatologic use contains desoximetasone as the active ingredient. Desoximetasone is a corticosteroid with the chemical name of pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16-methyl-, (11ß,16α)-. Desoximetasone has the molecular formula of C22H29FO4 and a molecular weight of 376.47. The CAS Registry Number is 382-67-2. The structural formula is:
Each gram of desoximetasone topical spray, 0.25% contains 2.5 mg of Desoximetasone USP in a clear, colorless liquid with the following inactive ingredients: butylated hydroxytoluene, citric acid anhydrous, diisopropyl adipate, isopropyl alcohol (23.4%), L-menthol, medium-chain triglycerides, mineral oil and sorbitan monooleate. Desoximetasone topical spray, 0.25% is co-packaged with a manual spray pump for installation by the pharmacist prior to dispensing to patients.
Two multi-center, randomized, double-blind, vehicle- controlled clinical trials were conducted in 239 subjects aged 18 years and older with moderate to severe plaque psoriasis of the body. In both trials, randomized subjects applied desoximetasone topical spray, 0.25% or vehicle spray to the affected areas twice daily for 4 weeks. Enrolled subjects had a minimum body surface area of involvement of 10%, and a Physician's Global Assessment score (PGA) of 3 (moderate) or 4 (severe).
Efficacy was assessed at Week 4 as the proportion of subjects who were considered a Clinical Success ("clear" (0) or "almost clear" (1) according to the PGA scale). Table 2 presents the efficacy results.
| Paramete r | Trial 1 | Trial 2 | ||
| Desoximetasone Topical Spray, 0.25% N=59 | Vehicle N=60 | Desoximetasone Topical Spray, 0.25% N=60 | Vehicle N=60 | |
| Clinical Success | 18 (30.5%) | 3 (5.0%) | 32 (53.3%) | 11 (18.3%) |
See FDA-approved patient labeling (Patient Information and Instructions for Use)
Inform patients of the following:
- Use this medication as directed by the physician. Do not use this medication for any disorder other than that for which it was prescribed.
- Desoximetasone topical spray, 0.25% is for external use only.
- Avoid contact with eyes and use on the face, axilla or groin.
- To minimize the risk of adverse reactions:
- do not bandage or otherwise cover or wrap the treated skin so as to be occlusive.
- discontinue therapy when control is achieved. If no improvement is seen within 4 weeks, contact the physician.
- do not use other corticosteroid-containing products with desoximetasone topical spray, 0.25% without first consulting with the physician.
- Advise patients that desoximetasone topical spray, 0.25%, may require periodic evaluation for HPA axis suppression. Topical corticosteroids may have other endocrine effects. [see Warnings and Precautions (5.1)].
- Advise women to use desoximetasone topical spray, 0.25% on the smallest area of skin and for the shortest duration possible while pregnant or breastfeeding. Advise breastfeeding woman not to apply desoximetasone topical spray, 0.25% directly to the nipple and areola to avoid direct infant exposure [see Use in Specific Populations (8.1 and 8.2].
- Report any signs of local or systemic adverse reactions including any visual symptoms to the physician.
- This medication is flammable; avoid heat, flame, or smoking when applying this product.
- Discard this product 30 days after dispensed by pharmacist.
LUPIN and the
are registered trademarks of Lupin Pharmaceuticals, Inc.Manufactured for:
Lupin Pharmaceuticals, Inc.
Naples, FL 34108
United States
Manufactured by:
Lupin Limited
Pithampur (M.P.) – 454 775
India
Revised: October 2024